Upstream Bio在ATS 2026国际会议上公布Verekitug二期Vibrant试验新数据,显示其改善CRSwNP合并哮喘患者的哮喘症状控制

美股速递
May 18

Upstream Bio在2026年美国胸科学会国际会议上,公布了其候选药物Verekitug在二期Vibrant临床试验中的最新数据。数据显示,对于同时患有慢性鼻窦炎伴鼻息肉和哮喘的患者,Verekitug在改善哮喘症状控制方面展现出积极效果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10